featured
Vupanorsen Lowers Triglycerides and Atherogenic Lipoproteins in Patients With Diabetes, Hepatic Steatosis, and Hypertriglyceridemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vupanorsen, an N-Acetyl Galactosamine-Conjugated Antisense Drug to ANGPTL3 mRNA, Lowers Triglycerides and Atherogenic Lipoproteins in Patients With Diabetes, Hepatic Steatosis, and Hypertriglyceridaemia
Eur Heart J 2020 Aug 29;[EPub Ahead of Print], D Gaudet, E Karwatowska-Prokopczuk, SJ Baum, E Hurh, J Kingsbury, VJ Bartlett, AL Figueroa, P Piscitelli, W Singleton, JL Witztum, RS Geary, S Tsimikas, L St L O'DeaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.